Clinical prognostic analysis showed that tumors with higher EHMT2 expression along with lower PTEN expression may have a poorer prognosis than tumors with other expression patterns in patients with NSCLC. The gene discussed is EHMT2; the disease is non-small cell lung carcinoma.